Dong-A Socio Holdings Sees 38% Profit Jump in Q2, Fueled by Bacchus Sales

Dong-A Socio Holdings has announced a significant double-digit growth in its second-quarter performance, largely attributed to robust sales of its iconic energy drink, Bacchus, and other over-the-counter (OTC) pharmaceuticals. The company reported a 38.3% surge in operating profit, reaching 39 billion won for the quarter ending June 30.

Consolidated revenue for the same period increased by 18.9% compared to the previous year, amounting to 412.4 billion won. This impressive financial result highlights the sustained popularity of Dong-A's products and effective market strategies.

The strong performance was primarily spearheaded by Dong-A Pharmaceutical, a crucial subsidiary. Its second-quarter revenue alone reached 228.2 billion won, demonstrating its significant contribution to the group's overall success. The company's focus on established brands like Bacchus, alongside a steady stream of OTC medications, appears to resonate well with consumers, leading to this notable financial upturn.